● Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

Condition: Achondroplasia · Sponsor: Ascendis Pharma A/S

PhasePhase 2

Planned participants72

Who can joinAll sexes, 0 Years to 2 Years

Healthy volunteersNo

About this study

This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.

This description comes directly from the study's public registry record.

Talk to the study team

Ascendis Registry Inquiries · +45 61242484 · asnd_registryinquiries@ascendispharma.com

Always discuss trial participation with your own doctor first.

Locations (18)

Ascendis Investigational Site	Saint Paul, Minnesota, United States	Recruiting
Ascendis Investigational Site	Houston, Texas, United States	Recruiting
Ascendis Investigational Site	Madison, Wisconsin, United States	Recruiting
Ascendis Investigational Site	Parkville, Australia	Recruiting
Ascendis Investigational Site	Linz, Austria	Recruiting
Ascendis Investigational Site	Montreal, Canada	Recruiting
Ascendis Investigational Site	Copenhagen, Denmark	Recruiting
Ascendis Investigational Site	Helsinki, Finland	Recruiting
Ascendis Investigational Site	Paris, France	Recruiting
Ascendis Investigational Site	Berlin, Germany	Recruiting
Ascendis Investigational Site	Cologne, Germany	Recruiting
Ascendis Investigational Site	Dublin, Ireland	Recruiting

+ 6 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06079398